Sumatriptan uncontrolled hypertension — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Avoid triptan supply and refer for clinical review
This scenario assesses Sumatriptan uncontrolled hypertension in a UK pharmacy practice context. Triptans are vasoconstrictors and are unsuitable in uncontrolled hypertension. The best answer is Avoid triptan supply and refer for clinical review because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.
Reference: BNF; NICE CKS